5-Amino-1MQ
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
At a glance
- Bioregulator
- oral, subcutaneous
- Not yet audited here; the reference library calls it emerging
- Sources differ. See the source
How much to draw
Full calculator →The reference does not report a single injectable amount for 5-Amino-1MQ, so the amount is yours to enter. The arithmetic is the same for any vial. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for 5-Amino-1MQ or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| Standard: 100 mg once daily · Low: 50 mg once daily · High: 150 mg once daily | once daily8 to 12 weeks on, 4 to 6 weeks off · 8 to 12 weeks on, 4 to 6 weeks off | oral | Peptide Dosing ProtocolsWhat it saysHideHalf-life: 4 to 7 hours. The most common research community target dose is 100 mg once daily. |
- once daily8 to 12 weeks on, 4 to 6 weeks off · 8 to 12 weeks on, 4 to 6 weeks off
- oral
- Peptide Dosing Protocols
What it saysHide
Half-life: 4 to 7 hours. The most common research community target dose is 100 mg once daily.
- Reconstitute each vial with 3.0 mL bacteriostatic (BAC) water for ~16.7 mg/mL; 2 vials = ~6 mL total. (Subcutaneous form; the compound is also taken orally.)
We have not published an audit on 5-Amino-1MQ. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
5-Amino-1MQ appears to block an enzyme in fat tissue that uses up a form of vitamin B3. With more B3 left over, cells can make more NAD+, a molecule cells use for energy, and in rodent studies body weight and fat fell without a change in food intake. Researchers link this to inhibition of NNMT (nicotinamide N-methyltransferase). No human trial has been published, so dose ranges come from scaling up mouse doses and from community use.
It works by blocking an enzyme called NNMT (nicotinamide N-methyltransferase), which, when elevated in fat tissue, depletes vitamin B3 necessary for NAD+ production. By inhibiting NNMT, it preserves B3, increases NAD+, and promotes fat cells to function more like lean tissue. [Source: Peptide Dosing Protocols]
Reported side effects
Seen in studies: there is no published human safety trial. What is known comes from rodent toxicity data and community reports, so it shows what has been reported, not what is known to be safe long term.
Reported by users: mild stimulant-like effects, such as warmth and a slightly faster resting heart rate, in the first 1 to 2 weeks. Trouble sleeping when it is used in the afternoon or evening. Mild stomach upset with oral capsules, stinging where it is injected, and lower exercise tolerance in the first weeks of cardio training.
Not ruled out: liver enzyme changes, cancer risk in people with a cancer history, long-term effects of repeated cycles, and interactions with medicines that are sensitive to methyl donors. These are theoretical or under-studied. Batch purity and capsule dose accuracy also vary by supplier, because it is sold under research-use-only labels.
Who should avoid it
People who are pregnant or breastfeeding: it has not been studied in these groups.
People with cancer, now or recently: NNMT has a complex role in cancer, and in some tumour types its activity helps the tumour grow.
People with liver disease: community use guides call for liver enzyme checks (ALT/AST) before and during use.
Children and teenagers: no safety data exists.
People on methyl-donor-sensitive medicines, such as some psychiatric drugs, methotrexate or high-dose methylated B-vitamin protocols: NNMT shares the methyl donor SAM, so interactions are possible in theory.
People with sleep disorders: its activating effect can worsen insomnia when it is used late in the day.
What gets monitored
Baseline ALT/AST check and recheck during long cycles. (reported by Peptide Dosing Protocols)
Common questions
What is 5-Amino-1MQ?
5-Amino-1MQ is short for 5-amino-1-methylquinolinium. It is a small lab-made molecule that blocks an enzyme called NNMT. All current evidence comes from cell culture and rodent studies.
Is 5-Amino-1MQ a peptide?
No. It is a small molecule, not a chain of amino acids, even though it is often sold alongside research peptides.
Is 5-Amino-1MQ FDA-approved?
No. The source records no FDA-approved use as of June 2026. No human clinical trial has been published.
How much 5-Amino-1MQ do people take?
Reported amounts and schedules for 5-Amino-1MQ differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
What is the injection dose for 5-Amino-1MQ?
Reported amounts and schedules for 5-Amino-1MQ differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.
Oral capsule or subcutaneous injection, which is better?
The source describes oral capsules as the standard route and cites better absorption. It reports stinging at the injection site with the subcutaneous route and mild stomach upset with capsules in some users. No human trial of either route has been published.
What are the main side effects?
Community reports mention mild stimulant-like effects, trouble sleeping when it is used late in the day, and mild stomach upset with capsules. There is no published human safety trial, so long-term effects are unknown.
Who should avoid 5-Amino-1MQ?
The source lists people who are pregnant or breastfeeding, people with active or recent cancer, people with liver disease, children and teenagers, people on methyl-donor-sensitive medicines, and people with sleep disorders. These cautions come from how the rodent studies were set up and what is known about NNMT, not from human safety data.
Sources
- 01Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology (2018)
- 02Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. PubMed (peer-reviewed) (2024)
- 03Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature (2014)
- 04Sampson CM, Dimet AL, Neelakantan H, et al. Combined nicotinamide N-methyltransferase inhibition and lean-diet substitution reduces body weight and liver fat in obese mice. Scientific Reports (2021)
- 05Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates muscle stem cells and progenitor cell function. Biochemical Pharmacology (2019)
- 06Pissios P. Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme. Trends in Endocrinology and Metabolism (2017)
- 07National Center for Biotechnology Information. PubChem Compound Summary for 5-Amino-1-methylquinolinium (5-Amino-1MQ). PubChem (2026)
- 08U.S. Food and Drug Administration. Drugs@FDA: search confirms no approved 5-Amino-1MQ product as of June 2026. FDA.gov (2026)
- 09ClinicalTrials.gov. Search results for 5-Amino-1MQ and NNMT inhibitor (no active human trials registered as of June 2026). ClinicalTrials.gov (2026)
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.